Eyenovia Stock Performance
| EYEN Stock | USD 0.09 0.02 15.55% |
The firm shows a Beta (market volatility) of 3.04, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Eyenovia will likely underperform. At this point, Eyenovia has a negative expected return of -1.61%. Please make sure to confirm Eyenovia's treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Eyenovia performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Eyenovia has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
1 | Acquisition by Strahlman Ellen R of 6744 shares of Eyenovia at 1.6018 subject to Rule 16b-3 | 09/06/2024 |
2 | Insider Trading | 09/25/2024 |
3 | Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05 percent for Post-Operative Inflammation and Pain Follo... | 09/26/2024 |
4 | Eyenovia Announces Share Offering and Warrant Sale for Growth - TipRanks | 09/30/2024 |
5 | Eyenovia Inc Q2 2024 Earnings Call Highlights Strategic Advances Amid Financial Challenges | 10/09/2024 |
6 | Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at theAmerican Academy of Ophthalmology 2024 Expo | 10/16/2024 |
7 | Acquisition by Andrew Jones of 200000 shares of Eyenovia at 0.5501 subject to Rule 16b-3 | 11/06/2024 |
8 | Eyenovia GAAP EPS of -0.11 in-line, revenue of 1.62M beats by 1.51M | 11/12/2024 |
9 | Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline | 11/15/2024 |
10 | Eyenovia Provides Update on Restructuring Efforts | 11/22/2024 |
11 | Eyenovia, Inc. Announces Pricing of 1.3 Million Registered Direct Offering | 11/25/2024 |
| Begin Period Cash Flow | 22.9 M |
Eyenovia |
Eyenovia Relative Risk vs. Return Landscape
If you would invest 55.00 in Eyenovia on August 30, 2024 and sell it today you would lose (45.71) from holding Eyenovia or give up 83.11% of portfolio value over 90 days. Eyenovia is currently does not generate positive expected returns and assumes 12.1985% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Eyenovia, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Eyenovia Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eyenovia's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Eyenovia, and traders can use it to determine the average amount a Eyenovia's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1319
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EYEN |
Estimated Market Risk
| 12.2 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.61 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Eyenovia is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eyenovia by adding Eyenovia to a well-diversified portfolio.
Eyenovia Fundamentals Growth
Eyenovia Stock prices reflect investors' perceptions of the future prospects and financial health of Eyenovia, and Eyenovia fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eyenovia Stock performance.
| Return On Equity | -9.15 | ||||
| Return On Asset | -0.93 | ||||
| Operating Margin | (516.61) % | ||||
| Current Valuation | 15.25 M | ||||
| Shares Outstanding | 95.44 M | ||||
| Price To Earning | (1.40) X | ||||
| Price To Book | 2.53 X | ||||
| Price To Sales | 282.33 X | ||||
| Revenue | 3.79 K | ||||
| Gross Profit | 12.4 M | ||||
| EBITDA | (24.11 M) | ||||
| Net Income | (27.26 M) | ||||
| Cash And Equivalents | 21.51 M | ||||
| Cash Per Share | 0.63 X | ||||
| Total Debt | 16.08 M | ||||
| Debt To Equity | 0.31 % | ||||
| Current Ratio | 2.14 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (23.84 M) | ||||
| Earnings Per Share | (0.59) X | ||||
| Market Capitalization | 8.87 M | ||||
| Total Asset | 28.78 M | ||||
| Retained Earnings | (145.49 M) | ||||
| Working Capital | 11.18 M | ||||
| Current Asset | 6.23 M | ||||
| Current Liabilities | 904.7 K | ||||
About Eyenovia Performance
By examining Eyenovia's fundamental ratios, stakeholders can obtain critical insights into Eyenovia's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Eyenovia is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 10.6 K | 11.1 K | |
| Return On Tangible Assets | (1.02) | (1.07) | |
| Return On Capital Employed | (1.32) | (1.39) | |
| Return On Assets | (0.95) | (0.99) | |
| Return On Equity | (3.03) | (3.18) |
Things to note about Eyenovia performance evaluation
Checking the ongoing alerts about Eyenovia for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Eyenovia help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eyenovia generated a negative expected return over the last 90 days | |
| Eyenovia has high historical volatility and very poor performance | |
| Eyenovia has some characteristics of a very speculative penny stock | |
| Eyenovia has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.79 K. Net Loss for the year was (27.26 M) with profit before overhead, payroll, taxes, and interest of 12.4 M. | |
| Eyenovia currently holds about 21.51 M in cash with (23.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Eyenovia has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Eyenovia, Inc. Announces Pricing of 1.3 Million Registered Direct Offering |
- Analyzing Eyenovia's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eyenovia's stock is overvalued or undervalued compared to its peers.
- Examining Eyenovia's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eyenovia's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eyenovia's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eyenovia's stock. These opinions can provide insight into Eyenovia's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyenovia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyenovia. If investors know Eyenovia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyenovia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.59) | Revenue Per Share 0.001 | Quarterly Revenue Growth 4 | Return On Assets (0.93) | Return On Equity (9.15) |
The market value of Eyenovia is measured differently than its book value, which is the value of Eyenovia that is recorded on the company's balance sheet. Investors also form their own opinion of Eyenovia's value that differs from its market value or its book value, called intrinsic value, which is Eyenovia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyenovia's market value can be influenced by many factors that don't directly affect Eyenovia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyenovia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyenovia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyenovia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.